Dr. Tauber is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
4400 Broadway St
Ste 202
Kansas City, MO 64111Phone+1 816-531-9100Fax+1 816-531-9105- Is this information wrong?
Summary
- Dr. Joseph Tauber is an ophthalmologist in Kansas City, MO. He specializes in cornea & external disease, refractive surgery and uveitis and is experienced in sjogren's syndrome, cataract surgery, corneal transplant surgery. He is also Chief Medical Officer for Brightstar Therapeutics and of Vital Tears.
Education & Training
- Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolFellowship, Cornea, External Diseases, and Refractive Surgery, 1988 - 1989
- Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolResidency, Ophthalmology, 1987 - 1989
- Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolFellowship, Ocular Immunology/Uveitis, 1987 - 1988
- Tufts Medical CenterResidency, Ophthalmology, 1984 - 1987
- Icahn School of Medicine at Mount Sinai (Beth Israel)Internship, Internal Medicine, 1983 - 1984
- Northwestern Medical Center1982 - 1983
- Harvard Medical SchoolClass of 1982
- Union CollegeBS, Biology and Chemistry, Summa Cum Laude, 1978
Certifications & Licensure
- MO State Medical License 1989 - 2025
- KS State Medical License 1997 - 2024
- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Member, Cornea Subcommittee American Academy of Ophthalmology Program Committee 2002-2006, 2006
- American Academy of Ophthalmology Achievement Award 2005
- National Eye Institute Individual NRSA Award (EY06052) Massachusetts Eye & Ear Infirmary, 1987-1989, 1989
- Join now to see all
Clinical Trials
- Dry Eye Assessment and Management Study Start of enrollment: 2014 Nov 01
- Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation Start of enrollment: 2014 May 01
- Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease Start of enrollment: 2014 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- Multi-symptom Relief with Propylene Glycol-Hydroxypropyl-Guar Nanoemulsion Lubricant Eye Drops in Subjects with Dry Eye Disease: A Post-Marketing Prospective Study.Bickle, K., Miller, J., Awisi-Gyau, D., Tauber, J.> ;Ophthalmology and Therapy. 2024 Feb 1
- 8 citationsEfficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical Trial.Esen K Akpek, David L Wirta, Johnathon E Downing, Joseph Tauber, John D Sheppard, Joseph B Ciolino, Alice S Meides, Sonja Krösser> ;JAMA Ophthalmology. 2023 May 1
- A phase 2a, double-masked, randomized, vehicle-controlled trial of VVN001 in subjects with dry eye disease.Joseph Tauber, David Evans, Bruce Segal, Xiao-Yan Li, Wang Shen, Caroline Lu, Gary D Novack> ;The Ocular Surface. 2023 Apr 1
- Join now to see all
Journal Articles
- Refractive Outcomes Following Excimer Laser Photorefractive Keratectomy for Myopia Using Two Different VISX Excimer Lasers.Cable M, Matta C, Piebenga L, Polepalle S, Steward C, Tauber J, Investigative Ophthalmology Visual Science 40 (4): S106
- Safety and Efficacy of Nedocromil Sodium Ophthalmic Solution 25 BID in Patients with Ocular Itch Associated With Allergic Conjunctivitis.Tauber J, Alocril Community Ocular Allergy Trial Study Group, Investigative Ophthalmology Visual Science 42(4) S910
- Efficacy and Safety of Combination Therapy with Brimonidine 0.2% and Latanoprost 0.005% Versus Fixed Combination Timolol 0.5%/Dorzolamide 2%Zabriskie N A, Ahmed I K, Cantor L B, Kent A B, Mundorf T, Tauber J, Rubin J M, Hoop J, Investigative Ophthalmology Visual Science 42 (4) S833
- Join now to see all
Books/Book Chapters
Authored Content
- Myths and Misconceptions About Autologous Serum for Dry EyeJune 2020
Press Mentions
- Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the American Society of Cataract and Refractive Surgery Annual MeetingApril 25th, 2022
- VivaVision Biotech Announces Positive Topline Results of VVN001 in the Phase 2 Clinical Study for the Treatment of Dry Eye DiseaseMarch 23rd, 2022
- Chutes & Ladders—Novartis Loses 2 Leaders, One to MiroBio, Another to a Video Game CompanySeptember 24th, 2021
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: